With 81.3 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.82 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $0.2875 whereas the lowest price it dropped to was $0.2225. The 52-week range on PIII shows that it touched its highest point at $1.35 and its lowest point at $0.18 during that stretch. It currently has a 1-year price target of $0.97. Beta for the stock currently stands at 0.99.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PIII was down-trending over the past week, with a drop of -6.20%, but this was up by 2.25% over a month. Three-month performance dropped to -26.77% while six-month performance fell -59.09%. The stock lost -82.67% in the past year, while it has gained 0.93% so far this year. A look at the trailing 12-month EPS for PIII yields -0.84 with Next year EPS estimates of -0.40. For the next quarter, that number is -0.19. This implies an EPS growth rate of 11.08% for this year and 28.84% for next year.
Float and Shares Shorts:
At present, 161.97 million PIII shares are outstanding with a float of 91.41 million shares on hand for trading. On 2024-10-31, short shares totaled 0.96 million, which was 58.999998 higher than short shares on 1727654400. In addition to Dr. Sherif Abdou F.A.C.E.P., FACP, M.D. as the firm’s Co-Founder, Vice Chairperson of the Board & Strategic Advisor, Dr. Amir Bacchus M.B.A., M.D. serves as its Co-Founder, Chief Medical Officer & Director.
Institutional Ownership:
Through their ownership of 0.24986 of PIII’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, PIII reported revenue of $362124000.0 and operating income of -$106990000.0. The EBITDA in the recently reported quarter was -$84872000.0 and diluted EPS was -$0.31.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PIII since 2 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PIII analysts setting a high price target of 1.0 and a low target of 0.25, the average target price over the next 12 months is 0.625. Based on these targets, PIII could surge 334.78% to reach the target high and rise by 8.7% to reach the target low. Reaching the average price target will result in a growth of 171.74% from current levels.
Analysts have provided yearly estimates in a range of -$0.51563 being high and -$0.61253 being low. For PIII, this leads to a yearly average estimate of -$0.56022.
